Solid Tumors
In solid tumors significantly high levels of chromosome abnormalities have been detected, but distinction between significant and irrelevant events has been a major challenge. Consequently, the application of cytogenetic technology as diagnostic, prognostic, or therapeutic tools for these malignancies has remained largely underappreciated. The emergence of FISH is particularly useful for solid malignancies, and the spectrum of their application is rapidly expanding to improve efficiency and sensitivity in cancer diagnosis, prognosis, and therapy selection, alone or with other diagnostic methods.
ON ERBB2, Her2/Neu (17q12) / SE 17
The Her2/Neu gene encodes a receptor tyrosine kinase involved in growth factor signaling. Overexpression of this gene is seen in about 20% of invasive breast cancers and is associated with poor survival. Her2 gene amplification is a permanent genetic change that results in this continuous overexpression of Her2.
A drug called trastuzumab (commonly known as Herceptin) has been developed to be effective against Her2-positive breast cancer. Her2/Neu amplification is also observed in a variety of other tumors, such as prostate, lung, colon and ovary carcinoma.
The Her2/Neu (17q12) specific DNA probe is optimized to detect copy numbers of the Her2/Neu (ERBB2) gene region at region 17q12. The SE 17 probe is included to facilitate chromosome identification.
Solid Tumors
In solid tumors significantly high levels of chromosome abnormalities have been detected, but distinction between significant and irrelevant events has been a major challenge. Consequently, the application of cytogenetic technology as diagnostic, prognostic, or therapeutic tools for these malignancies has remained largely underappreciated. The emergence of FISH is particularly useful for solid malignancies, and the spectrum of their application is rapidly expanding to improve efficiency and sensitivity in cancer diagnosis, prognosis, and therapy selection, alone or with other diagnostic methods.
ON ERBB2, Her2/Neu (17q12) / SE 17
The Her2/Neu gene encodes a receptor tyrosine kinase involved in growth factor signaling. Overexpression of this gene is seen in about 20% of invasive breast cancers and is associated with poor survival. Her2 gene amplification is a permanent genetic change that results in this continuous overexpression of Her2.
A drug called trastuzumab (commonly known as Herceptin) has been developed to be effective against Her2-positive breast cancer. Her2/Neu amplification is also observed in a variety of other tumors, such as prostate, lung, colon and ovary carcinoma.
The Her2/Neu (17q12) specific DNA probe is optimized to detect copy numbers of the Her2/Neu (ERBB2) gene region at region 17q12. The SE 17 probe is included to facilitate chromosome identification.